Dr. Dmitry Dmitrievich Genkin was Director of the Company. He was previously a party to a consulting agreement with the Company that was mutually terminated on August 1, 2017, pursuant to which he was paid approximately $190,000 from January 1, 2016 through August 1, 2017. Pursuant to the consulting agreement, Dr. Genkin provided advisory services related to the Company’s XBIO-101 and Oncohist programs. Dr. Genkin also previously served as a member of the Board until May 3, 2016, and the Company paid Dr. Genkin $1,074 for his services as a director during 2016.
Dmitry Genkin is 51, he's been the Independent Director of Xenetic Biosciences Inc since 2017. There are 10 older and 2 younger executives at Xenetic Biosciences Inc. The oldest executive at Xenetic Biosciences Inc is Roger Kornberg, 73, who is the Director.
Dmitry's mailing address filed with the SEC is 40 SPEEN STREET, SUITE 102, , FRAMINGHAM, MA, 01701.
xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid
Xenetic Biosciences Inc executives and other stock owners filed with the SEC include: